CJC-1295 + Ipamorelin Blend
NeuroprotectionNeurology research on CJC-1295 + Ipamorelin Blend examines whether this ghrh + ghrp combination produces measurable CNS effects beyond peripheral activity. The cognitive case rests on three convergent threads: cjc-1295 stimulates the ghrh receptor; ipamorelin stimulates the ghrelin/ghsr receptor the two pathways converge on the same somatotroph but use independent receptors, producing a multiplicative rather than additive gh pulse. ipamorelin's selectivity avoids the cortisol/prolactin elevation seen with ghrp-6 and ghrp-2.; downstream consequences for monoamine and neurotrophic signalling; and reduction of chronic neuroinflammation. CJC-1295 + Ipamorelin Blend is dosed at 100 mcg CJC + 200 mcg ipamorelin 1-3x daily subq via subq in cognitive-focused protocols, with the Mixed pharmacokinetic profile shaping receptor occupancy timing.
Key Takeaways
Cognitive lens: CJC-1295 + Ipamorelin Blend acts as a modulator with both restorative and modest activating components for cognitive endpoints. CNS access pattern: BBB transport plus vagal-afferent gut-brain signalling and cerebral vascular effects. Mechanism: CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. Neuro dose: 100 mcg CJC + 200 mcg ipamorelin 1-3x daily subq via subq; cognitive effects accumulate across 4-8 weeks. Cognitive stack partners: Semax, Selank, Semax + Selank Blend.
CJC-1295 + Ipamorelin Blend's neurological relevance starts with how the compound reaches the central nervous system. CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. The two pathways converge on the same somatotroph but use independent receptors, producing a multiplicative rather than additive GH pulse. Ipamorelin's selectivity avoids the cortisol/prolactin elevation seen with GHRP-6 and GHRP-2. Direct blood-brain barrier transport is rarely the dominant route for peptide compounds; vagal-afferent gut-brain signalling and effects on cerebral vasculature where the barrier is locally compromised typically produce the CNS phenotype. The detail follows.
Central nervous system access
CJC-1295 + Ipamorelin Blend reaches the central nervous system through one or more of three documented routes: direct blood-brain barrier transport, vagal-afferent signalling via the gut-brain axis, and direct action on cerebral vasculature in regions where the barrier is locally compromised. The compound's subq route(s) and Mixed half-life set the timeline for CNS exposure. CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. The CNS-relevant phenotype that emerges from this mechanism is the substrate of the cognitive effects described below.
Receptor pharmacology and selectivity profile
CJC-1295 + Ipamorelin Blend's receptor-level pharmacology determines its selectivity profile and its overlap with companion peptides. CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. The two pathways converge on the same somatotroph but use independent receptors, producing a multiplicative rather than additive GH pulse. Ipamorelin's selectivity avoids the cortisol/prolactin elevation seen with GHRP-6 and GHRP-2. The selectivity (or lack thereof) for the principal target relative to off-target receptors is the basis for both the clinical phenotype and the side-effect profile. In stack design this matters: pairing CJC-1295 + Ipamorelin Blend with peptides engaging the same primary receptor produces competition rather than synergy.
Cerebral perfusion and the structural cognitive substrate
Cognitive function depends on adequate cerebral perfusion, intact endothelial signalling, and a low chronic-inflammatory tone in the brain parenchyma. CJC-1295 + Ipamorelin Blend, with its CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor The two pathways converge on the same somatotroph but use independent receptors, producing a multiplicative rather than additive GH pulse. Ipamorelin's selectivity avoids the cortisol/prolactin elevation seen with GHRP-6 and GHRP-2. mechanism, contributes to this substrate rather than producing acute stimulant-like activation. Across the cognitive applications outlined below, what users describe is restoration of baseline rather than amplification above it. The Mixed pharmacokinetic profile supports this restorative rather than stimulant phenotype.
HPA Axis Modulation is one of the more-reported subjective benefits of CJC-1295 + Ipamorelin Blend across cognitive-focused user cohorts. The mechanism is plausible given the compound's neurotrophic and anti-inflammatory profile; the effect size depends substantially on baseline status.
Where CJC-1295 + Ipamorelin Blend is used for chronic neuroinflammation, the dosing window is typically 4–8 weeks with re-evaluation at the end of cycle. Stacking with selank or semax is common in this use case; pure-isolated dosing is also viable for first-cycle users.
For post-tbi recovery, CJC-1295 + Ipamorelin Blend is most-relevant in users whose cognitive complaints track with chronic neuroinflammation or post-injury recovery. Effect size is modest but consistent across well-tolerated dose ranges, with typical response window of 4–8 weeks.
Neurogenesis is one of the more-reported subjective benefits of CJC-1295 + Ipamorelin Blend across cognitive-focused user cohorts. The mechanism is plausible given the compound's neurotrophic and anti-inflammatory profile; the effect size depends substantially on baseline status.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 100 mcg CJC + 200 mcg ipamorelin | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 60 mcg CJC + 200 mcg ipamorelin | 4–6 weeks initial cycle |
| Neuroprotection focus | SubQ | 100 mcg CJC + 200 mcg ipamorelin | 1-3x daily SubQ |
| Maintenance phase | SubQ | 70 mcg CJC + 200 mcg ipamorelin | Ongoing with periodic pauses |
Dose timing for CJC-1295 + Ipamorelin Blend is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.
CJC-1295 + Ipamorelin Blend stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from the cognitive neuroscience community.
- CJC-1295 + Ipamorelin Blend + Semax: Elevates BDNF and NGF in hippocampus and cortex. Pairs naturally with CJC-1295 + Ipamorelin Blend's mechanism in cognitive / neurological protocols.
- CJC-1295 + Ipamorelin Blend + Selank: Modulates GABA-A receptor systems indirectly. Pairs naturally with CJC-1295 + Ipamorelin Blend's mechanism in cognitive / neurological protocols.
- CJC-1295 + Ipamorelin Blend + Semax + Selank Blend: Semax raises BDNF and modulates dopamine systems; Selank stabilises GABAergic and serotonergic tone. Pairs naturally with CJC-1295 + Ipamorelin Blend's mechanism in cognitive / neurological protocols.
- CJC-1295 + Ipamorelin Blend + DSIP: Mechanism remains incompletely characterised. Pairs naturally with CJC-1295 + Ipamorelin Blend's mechanism in cognitive / neurological protocols.
Lowest-side-effect profile of GH-releasing stacks. Site reactions and mild flushing possible.
Lens-specific safety considerations for cognitive / neurological use of CJC-1295 + Ipamorelin Blend: Lowest-side-effect profile of GH-releasing stacks. Site reactions and mild flushing possible. Additional cognitive / neurological monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| CJC-1295 + Ipamorelin Blend | GHRH + GHRP combination | Mixed | Neuroprotection |
| Semax | ACTH-derived nootropic heptapeptide | CNS effect hours; plasma minutes | A Russian-developed analogue of ACTH(4-10) extended with a Pro-Gly-Pro tail for proteolytic stability — a clinically used nootropic and stroke recovery agent |
| Selank | Tuftsin-derived heptapeptide anxiolytic | CNS effect lasts hours; plasma short | A Russian-developed heptapeptide derived from tuftsin — anxiolytic without sedation, supported by clinical trial data in generalised anxiety disorder |
| DSIP | Neuropeptide (sleep) | ~7 min plasma; CNS effects longer | A short neuropeptide isolated from sleeping rabbits in 1977, of interest for its modulation of delta-wave sleep and stress resilience |
| Pinealon | Khavinson tripeptide (pineal-derived) | Short plasma; durable tissue effects | A Khavinson pineal-derived tripeptide of glutamate-aspartate-arginine, studied for neuroprotection and cognitive function in aged and ischemic models |
How long until I notice cognitive effects?
Best route for cognitive applications — injection or oral?
Does CJC-1295 + Ipamorelin Blend cross the blood-brain barrier?
Is CJC-1295 + Ipamorelin Blend appropriate alongside SSRIs or other psychiatric medications?
What is the mechanism of action of CJC-1295 + Ipamorelin Blend?
How should CJC-1295 + Ipamorelin Blend be stored and reconstituted?
Start a CJC-1295 + Ipamorelin Blend Protocol
Alukard provides physician-supervised cognitive protocols with GMP-certified CJC-1295 + Ipamorelin Blend and GMP-certified compounds and comprehensive neurological assessments.
Get ProtocolQuick Facts
- Molecular weight
- Variable
- Half-life
- Mixed
- WADA
- Both components banned (S2)
- FDA
- Unapproved
- Research
- Off-label clinical use; mechanistic studies
Stack Partners
All cognitive / neurological applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for CJC-1295 + Ipamorelin Blend unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Cognitive / Neurological Protocol for CJC-1295 + Ipamorelin Blend
Alukard provides physician-supervised cognitive protocols with GMP-certified compounds and comprehensive neurological assessments.
HIPAA Compliant · GMP Certified · Physician Supervised